Provided by Tiger Trade Technology Pte. Ltd.

ETF & Stock Investment

2,091.45
+15.760.76%
Number of Gainers:682
Number of Losers:315
Number of Flat:26
PE:- -
High:2,096.63
Open:2,075.69
Low:2,075.69
Close:2,075.69
Volume:6.21B
Turnover:696.72B
Market Cap:97.36T
Float Cap:91.13T

Loading ...

Equity-Based Circuit Breaker Halts Trading in EUREN.E Shares

TIPRANKS
·
Sep 30

General Motors launches OnStar Fleet Intelligence platform

TIPRANKS
·
Sep 30

Morgan Stanley Currently Down Seven Consecutive Days, on Track for Longest Losing Streak Since January 2024

Dow Jones
·
Sep 30

PayPoint Directors Reinvest Interim Dividend Through Share Incentive Plan

TIPRANKS
·
Sep 30

QSE Taps Threat Intelligence Veteran to Drive Post-Quantum Cybersecurity Push

TIPRANKS
·
Sep 30

Lode Gold Bolsters Fremont Mine Team With Senior Technical Advisor Appointment

TIPRANKS
·
Sep 30

Avalon and Confederation College Team Up on Workforce Plan for Lake Superior Lithium Refinery

TIPRANKS
·
Sep 30

BHP Group Ltd Stock (BHP) Moved Up by 3.25% on Sep 30: What Investors Need To Know

TradingKey
·
Sep 30

Snowflake Inc Stock (SNOW) Moved Up by 3.38% on Sep 30: What Investors Need To Know

TradingKey
·
Sep 30

Freeport-McMoRan Inc Stock (FCX) Moved Up by 4.52% on Sep 30: What Investors Need To Know

TradingKey
·
Sep 30

Southern Copper Corp Stock (SCCO) Moved Up by 3.87% on Sep 30: What Signal Does It Send?

TradingKey
·
Sep 30

Franco-Nevada Corp Stock (FNV) Moved Down by 7.84% on Sep 30: What Signal Does It Send?

TradingKey
·
Sep 30

Block Inc put volume heavy and directionally bearish

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

PayPoint Dividend Reinvestment Plan Buys Shares at GBP 6.395 Each for Directors Wiles, Harding

Reuters
·
Sep 30

Ford F-150 Supplier Disruption Impacting 3Q Wholesale Numbers but Issue Resolved, CEO Says

THOMSON REUTERS
·
Sep 30